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Abstract
Background: Nigeria is one of  the 30 high burden countries for drug resistant tuberculosis (DR-TB). This study assessed the 
prevalence and factors associated with rifampicin resistant tuberculosis (RR-TB) in a secondary referral hospital in Lagos State 
Nigeria.
Methods: A retrospective review of  presumptive TB register of  patients screened for Mycobacterium tuberculosis (MTB) and RR-
TB using Xpert MTB/RIF assay at Mainland hospital between January 1 2012 and December 31 2016 was conducted.
Results: A total of  2497 clients were screened for MTB and RR-TB during the study period. The majority (51.4%) were between 
25 – 44 years. Male: Female ratio was 1:0.8. Of  the 2497 clients screened, MTB was detected in 942 (37.7%) out of  which 220 
(23.4%) had RR-TB. Age (AOR 1.8, 95%CI 1.3- 2.6, p = 0.001), symptomatic contact with DR-TB patients (AOR 3.3, 95%CI 
2.1-5.1, p <0.001) and type of  TB (AOR 2.9, 95% CI 1.7 – 5.0, <0.001) were associated with RR-TB after adjusting for age, 
gender, HIV status and symptomatic contacts with DR-TB patients.
Conclusion: The prevalence of  RR-TB in new and previously treated TB patients was high in this study. Urgent steps are need-
ed to avert an impending RR-TB epidemic
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Introduction
The emergence of  multidrug-resistant tuberculosis 
(MDR-TB) defined as resistance to at least rifampicin and 
isoniazid and rifampicin-resistant TB (RR-TB) has been 
a major obstacle to TB control globally.1 A World Health 
Organization (WHO) report indicated that 580,000 new 
cases of  MDR/RR-TB were notified in 2015 and an esti-
mated 250,000 MDR/RR-TB patients died in 2015.2  Sur-
veillance data show that about 4% of  new and 21% of  
previously treated TB cases had MDR/RR-TB in 2015.3 
Although there has been an increase in TB and MDR/
RR-TB case notifications, the gaps in case detection and 
treatment remain due to under reporting (in countries 
with large private sector) and under diagnosis (due to 
physical and financial barriers).2
The TB burden in Nigeria is one of  the highest in the 
world and Nigeria is one of  the 14 countries on the high 
burden lists for TB, MDR-TB and TB/HIV.2 In addition, 
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Nigeria is one of  the six countries contributing 60% of  
the 10.4 million new cases in 2015 and one of  the five 
countries that accounted for over 60% gap between es-
timated number of  incident MDR/RR-TB cases and 
MDR-TB enrolment in 2015.2 A meta-analysis of  the 
prevalence of  drug resistant TB (DR-TB) in Nigeria indi-
cated that 6% and 32% of  newly and previously treated 
TB cases respectively had MDR-TB.4
Gene Xpert® MTB/RIF (Xpert) (Cepheid Inc. New Jer-
sey, USA) for Mycobacterium tuberculosis (MTB) detection 
was endorsed by the WHO in 2010.5-7 It offers a platform 
for the integration of  TB and HIV activities in high bur-
dened TB and HIV settings8. The Xpert MTB/RIF is a 
point of  care automated diagnostic test that can identify 
the DNA of  Mycobacterium tuberculosis (MTB) and rifam-
picin resistance. It has high sensitivity and specificity at 
97.6% and 99.8% respectively.9
 
The use of  Xpert MTB/RIF assay commenced in Nige-
ria in 2012 and the programme was implemented by the 
KNCV TB Foundation in partnership with the Nigerian 
government, the support of  the United States Agency for 
International Development (USAID) and the supervi-
sion of  the National TB Programme (NTP).10 The use of  
Xpert MTB/RIF assay by the Lagos State TB and Lep-
rosy Control Programme (LSTBLCP) started in 2012. At 
inception, the Xpert assay was limited to priority groups 
which includes known symptomatic contacts of  DR-TB 
for adults and all child contacts of  DR-TB patients, all 
previously treated drug susceptible TB cases (treatment 
failure, relapse, treatment after loss to follow up and oth-
er previously treated patients) and TB/HIV co-infected 
patients. However, since 2016 the NTP recommended 
Xpert MTB/RIF assay for all presumptive TB patients in 
centers where it is available.11 This present study assessed 
the prevalence and factors associated with RR-TB in a 




A retrospective review of  presumptive TB register of  
patients screened for Mycobacterium tuberculosis (MTB) and 
RR-TB using Xpert MTB/RIF assay at Mainland hospi-
tal between January 1 2012 and December 31 2016 was 
conducted.
Study background
This study was conducted at Mainland Hospital in La-
gos state Nigeria. Mainland Hospital is a secondary refer-
ral facility established in 1930 as a sanitorium. Formally 
known as Infectious Disease Hospital (IDH), the name 
was changed to Mainland Hospital in 2003. The hospital 
is a referral hospital for treatment of  infectious diseases 
like TB, HIV/AIDS, MDR-TB, Cholera, Ebola virus dis-
ease and Lassa fever in Lagos state and its environ. The 
bed capacity of  the hospital is 100 out of  which 40 was 
designated for MDR-TB patients. The MDR-TB com-
plex (the only one in the state) was commissioned 2012 
by the Lagos State Government in collaboration with 
USAID. That same year, the programmatic management 
of  DR-TB patients commenced in the hospital. MDR-
TB patients were admitted for the entire duration of  the 
intensive phase (8 months), however treatment during 
the continuation phase was done on out-patient basis. In 
2014, community MDR-TB management commenced; 
this involved treatment of  MDR-TB patients in the com-
munity. Health workers were assigned to MDR-TB pa-
tients to monitor treatment and administer the injections.
Lagos state is located in SouthWest Nigeria with the es-
timated population of  12,155,337 in 2015.12 Although 
Lagos State is one of  the smallest state in the country, it 
is the commercial nerve center of  Nigeria. About 11% 
of  Nigerian population live in Lagos state and it has a 
total of  20 LGAs and 37 local council development areas 
(LCDAs)
 
Programmatic Management of  Drug Resistant TB 
in Lagos State
The LSTBLCP is responsible for the coordination of  TB 
control activities in Lagos state. All presumptive TB pa-
tients are expected to do Xpert MTB/RIF assay in the 
state to determine their bacteriological status and resis-
tance to rifampicin. Patients with positive MTB and ri-
fampicin resistance were sent for Line Probe Assay (LPA) 
and Culture. Other baseline investigations like electro-
lytes and urea, creatinine, urinalysis, full blood count, liv-
er function test, hepatitis B surface antigen, chest X-ray, 
thyroid function test, audiometry and HIV tests were also 
conducted.
Drug management of  MDR/RR-TB patients is for 20 
months divided into 8 months intensive phase and 12 
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months continuation phase. Levofloxacin, Cycloserine, 
Prothinamide, Kanamycin/ Capromycin, Pyrazinamide 
and Pyridoxine were drugs used during the intensive 
phase. Kanamycin or Capromycin is excluded in the con-
tinuation phase. HIV counseling and testing was offered 
to all presumptive TB patients. Patients with HIV co-in-
fection were offered anti-retroviral drugs two weeks after 
DR-TB treatment initiation if  they were not previously 
on anti-retrovirals.
Data analysis
Statistical Package for Social Sciences (SPSS) IBM ver-
sion 22 was used for data analysis. Numerical variables 
were presented in percentages, mean and standard de-
viation. Categorical variables were compared using chi 
squared test. Rifampicin resistance was the outcome vari-
able. Crude and adjusted odds ratio of  associated factors 
of  the outcome variable (age, gender, HIV status, symp-
tomatic contact with MDR patients and type of  TB) were 
determined. Confidence interval was set at 95% and p 
<0.05 was considered significant for all statistical tests.
 
Ethical issues
Permission to use data was obtained from the manage-




A total of  2497 client were screened for MTB and RR-
TB during the study period. The majority (51.4%) were 
between 25 – 44 years. There were more males (55%) 
than females (45%). About 35% had HIV co-infection. 
Of  the 2497 clients screened, MTB was detected in 942 
(37.7%) while 166 (6.6%) were invalid. Among the MTB 
cases found, 220 (23.4%) had RR-TB as shown in Ta-
ble 1. The proportion of  clients screened for MTB and 
RR- TB increased from 11% in 2012 to 32.9% in 2016. 
However, the proportion of  MTB positive cases detected 
declined from 49.3% in 2012 to 38.4% in 2016. In addi-
tion, the proportion of  RR-TB cases detected reduced 
from 48.9% in 2012 to 13% in 2016 (Table 1).
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Table 1: Characteristics of presumptive TB clients seen between 2012 and 2016
Variables 2012
n = 274 
(%)
2013
n = 400 (%)
2014
n = 496 
(%)
2015
n = 505 (%)
2016
n = 822 (%)
Total
n = 2497 (%)
Age group
0 – 14 4 (1.5) 8 (2.0) 12 (2.4) 11 (2.2) 12 (1.5) 47 (1.9)
15 – 24 45 (16.4) 60 (15.0) 58 (11.7) 61 (12.1) 93 (11.3) 317 (12.7)
25 – 34 70(25.5) 100 (25.0) 108 (21.8) 169 (33.5) 180 (21.9) 627 (25.1)
35 – 44 68 (24.8) 106 (26.5) 127 (25.6) 107 (21.2) 249 (30.3) 657 (26.3)
45 – 54 51 (18.6) 80 (20.0) 110 (22.2) 48 (9.5) 176 (21.4) 465 (18.6)
55 – 64 24 (8.8) 32 (8.0) 50 (10.1) 55 (10.9) 83 (10.1) 244 (9.8)
≥ 65 12 (4.4) 14 (3.5) 31 (6.3) 54 (10.7) 29 (3.5) 140 (5.6)
Gender
Male 154 (56.2) 229 (57.3) 277 (55.8) 247 (48.9) 466 (56.7) 1373 (55.0)
Female 120 (43.8) 171 (42.8) 219 (44.2) 258 (51.1) 356 (43.3) 1124 (45.0)
HIV result
Positive 33 (12.0) 156 (39.0) 160 (32.3) 200 (39.6) 312 (38.0) 861 (34.5)
Negative 161 (58.8) 161 (40.3) 320 (64.5) 282 (55.8) 487 (59.2) 1411 (56.5)
Unknown 80 (29.2) 83 (20.8) 16 (3.2) 23 (4.6) 23 (2.8) 225 (9.0)
MTB detection 
Negative 118 (43.1) 170 (42.5) 274 (55.2) 388 (76.8) 439 (53.4) 1389 (55.6)
Positive 135 (49.3) 181 (45.3) 216 (43.5) 94 (18.6) 316 (38.4) 942 (37.7)
invalid 21 (7.7) 49 (12.3) 6 (1.2) 23 (4.6) 67 (8.2) 166 (6.6)
Rifampicin 
resistance
n = 135 (%) n = 181 (%) n = 216 
(%)
n = 94 (%) n = 316 (%) n = 942 (%)
No 69 (51.1) 124 (68.5) 182 (82.3) 72 (76.6) 275 (87.0) 722 (76.6)
Yes 66 (48.9) 57 (31.5) 34 (15.7) 22 (23.4) 41 (13.0) 220 (23.4)
474
Figure 1 shows the indication for Xpert MTB/RIF assay. 
The majority (43.3%) were screened for RR-TB because 
of  symptomatic contact with DR-TB patients. Other rea-
sons for Xpert MTB/RIF assay includes PLHIV with 
symptoms of  TB (21.7%), TB relapse (13.4%) and failed 
six months regimen (3.2%). The regression analysis of  
the factors associated with RR-TB is shown in Table 2. 
 
 
Figure 1: Reasons for Xpert MTB/RIF assay 
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Table 2: Regression analysis of factors associated with DR-TB 
 
Variable                                 MDR/RIF Positive    MDR/RIF Negative               COR (95%CI), p                   AOR (95%CI), p 
Age group (years) 
< 45                                         137 (20.2)                    541 (79.8)                                1                                              1            
≥ 45                                         83 (31.4)                      181 (68.6)                                1.8 (1.3 – 2.5), <0.001                        1.8 (1.3 – 2.6), 0.001 
  
Gender 
Male                                        148 (25.9)                    424 (74.1)                                1.4 (1.0 – 2.0), 0.023               1.4 (0.9 – 1.9), 0.099         
Female                                     72 (19.5)                      298 (80.5)                                1                                              1                        
  
HIV status 
Negative                                  142 (22.2)                    497 (77.8)                                1.03 (0.7 – 1.56), 0.866           1.2 (0.8 – 1.9), 0.280 
Positive                                   42(21.6)                      152 (78.4)                                1                                              1 
Unknown#                               36 (33.0)                      73 (67.0)                      
  
Symptomatic contact with 
MDR patient 
Yes                                          141 (29.2)                    342 (70.8)                                2.0 (1.4 – 2.7), <0.001                        3.3 (2.1 – 5.1), <0.001 
No                                           79 (17.2)                      380 (82.8)                                1                                              1            
  
Type of TB 
Retreatment cases                   51 (26.7)                      140 (73.3)                                1.25 (0.86 – 1.83), 0.220         2.9 (1.7 – 5.0),       <0.001 
New                                        169 (22.5)                    582 (77.5)                                1                                              1 
 
NB: # = Not included in the analysis 
Age, symptomatic contact with DR-TB patients and type 
of  TB were factors associated with RR-TB. Significantly 
higher proportion of  TB patients aged 45 years and old-
er (31.4%) had rifampicin resistance compared with pa-
tients below 45 years (20.2%) AOR 1.8 (95%CI 1.3- 2.6) 
p = 0.001. The odds for symptomatic contact of  DR-
TB patients to develop rifampicin resistance was about 
three-fold higher than patients without symptomatic 
contact with DR-TB patients AOR 3.3, (95%CI 2.1-5.1), 
p <0.001. The proportion of  RR-TB among previous-
ly treated TB patients was higher (26.7%) than among 
newly diagnosed TB patients (22.5%) and the chance of  
developing RR-TB was three times more in patients pre-
viously treated for TB AOR 2.9 (95%CI 1.7 – 5.0) after 
adjusting for age, gender, HIV status and symptomatic 
contacts with DR-TB patients.
Discussion
The prevalence of  RR-TB was 23.4% in this study (22.5% 
and 26.7% among new and previously treated TB patients 
respectively). This finding is high compared to what was 
reported in studies from Southern and Northern part 
of  Nigeria, Ethiopia and Burundi.13-16 However, studies 
from another Southern state in Nigeria indicated a higher 
prevalence than what was found in this study.17 A sys-
tematic review of  the prevalence of  DR-TB in Nigeria 
showed that the prevalence of  DR-TB in the country var-
ied across geographical regions, settings and the methods 
used.4 The high prevalence obtained in our study may be 
due to the study setting. Mainland hospital is a referral 
hospital in Lagos State for TB and MDR-TB. Presump-
tive DR-TB patients were referred from other hospitals 
in the state for Xpert MTB/RIF. The reducing trend in 
the prevalence of  DR-TB in this study may be due to the 
increase in the number of  Xpert MTB/RIF sites in the 
state. The Xpert MTB/RIF sites in Lagos increased from 
7 in 2013 to 27 in 2016. In addition, there was a change in 
policy regarding the use of  Xpert MTB/RIF within the 
study period. Xpert MTB/RIF assay which was initial-
ly limited to priority groups such as TB/HIV co-infect-
ed patients, symptomatic contact of  DR-TB adults and 
previously treated drug sensitive TB patients was recom-
mended for all presumptive TB patients by the NTP.11
Findings from systematic review on the prevalence of  
DR-TB in Nigeria and Ethiopia4,18 have shown that the 
current WHO estimate for new and previously treated 
TB patients for both countries were low which is proof  
that the burden of  DR-TB in Nigeria and other high TB 
burden countries in Africa is probably bigger than we an-
ticipated.2
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Many studies have demonstrated that history of  previ-
ous TB treatment is a strong risk factor for MDR-TB.19–22 
This could be due to poor quality of  anti-TB drugs used, 
repeated, inappropriate intake of  medications and poor 
management of  drug sensitive TB. A survey which ana-
lyzed data from 11 countries indicated that the chance of  
developing resistant TB increased with the length of  time 
of  exposure to anti-TB drugs.23 In this study, the chance 
of  developing RR-TB was about three fold higher among 
patients previously treated for TB than new TB patients. 
Before the introduction of  Xpert MTB/RIF assay, the 
NTP recommended the addition of  streptomycin to the 
anti-TB regimen of  previously treated TB patients which 
prolonged the exposure and consequent resistance to an-
ti-TB drugs.
In this study, the chance of  developing RR-TB was higher 
among patients with symptomatic contact with a known 
DR-TB patient than those without contact. This finding 
underscores the continual spread of  DR-TB in the com-
munity mostly due to failure to promptly diagnose pre-
sumptive DR-TB patient and early treatment initiation. A 
WHO report showed that of  the 1241 MDR/RR-TB cas-
es diagnosed in 2015, about 50% were enrolled for treat-
ment. In addition, Nigeria is one of  the five countries 
responsible for over 60% gap between incident MDR/
RR-TB cases and treatment enrolment2.
The chance of  RR-TB was about two-fold higher among 
patients aged 45 years and above than the younger age 
group in this study similar to what was reported in a study 
from Northern Nigeria.24 The association between age 
and MDR-TB is not consistent. While studies form Nige-
ria, South Africa and Ethiopia have demonstrated a high-
er prevalence of  DR- TB in the lower age groups,13,25-27 
another Nigerian study showed no significant difference 
between age and DR-TB. The population structure of  the 
study settings may account for the inconsistent findings. 
However, surveillance data from Central and Eastern Eu-
rope have shown that prevalence of  MDR-TB peaks in 
young adulthood.27
There was no gender difference in the prevalence of  RR-
TB in this study similar to what was reported from oth-
er Nigerian studies.13,22,25 Studies from the Northern and 
Southern part of  Nigeria and South Africa showed that 
the prevalence of  DR-TB was significantly higher among 
males.14,24,26,28 Poor health seeking behavior among men, 
social stigma and cultural habits were adduced for the 
high prevalence of  DR-TB among men.28
 
Limitation
The issue of  missing and incomplete data is a major lim-
itation of  this study like any other retrospective survey. 
Available complete data was used for analysis and estima-
tion of  the RR-TB prevalence.
 
Conclusion
The prevalence of  RR-TB in new and previously treat-
ed TB patients was high in this study. Reduction of  the 
prevalence of  MDR/RR-TB is a daunting task. Proactive 
measures are needed urgently to address the challenge of  
prompt diagnosis and early initiation of  DR-TB treat-
ment to reduce spread of  DR-TB in the community. In 
addition, the LSTBLCP must put mechanisms in place to 
ensure adequate treatment of  drug sensitive TB.
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